Pediatrix Medical Group, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Pediatrix Medical Group, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	3,183	3,253	1,723	1,780	1,734	1,911	1,972	1,995	2,013	1,914
General and administrative	373	386	232	245	249	263	231	228	238	241
Operating expenses	2,611	2,798	1,475	1,608	1,636	1,708	1,799	1,987	2,082	1,705
Operating income	572	455	248	172	98.1	203	173	7.32	-68.7	209
Interest expense	63.1	74.6	92.9	119	110	68.7	39.7	42.1	40.7	36
Other non-operating income	-57.9	-69.2	-82.2	-113	-91	-67.7	-91.3	-55.7	-32.6	7.62
Pre-tax income	514	386	166	58.8	7.15	135	81.4	-48.4	-101	216
Income tax	189	80.2	44.7	16.6	16.7	27.2	18.8	12	-2.27	51
Net income to minority interests	-0.32				0	-0.03	-0	0	0
Net income	325	320	269	-1,498	-796	131	66.3	-60.4	-99.1	165
EBITDA	661	534	273	198	127	235	208	43.5	-36.5	231
EPS, basic	3.52	3.47	2.95	-17.94	-9.55	1.54	0.79	-0.73	-1.19	1.97
EPS, diluted	3.49	3.45	2.93	-17.83	-9.55	1.53	0.79	-0.73	-1.19	1.94
Shares, basic (weighted)	92.4	92.4	91.1	83.5	83.4	84.8	83.5	82.2	83.3	84.1
Shares, diluted (weighted)	93.1	93	91.6	84	83.4	85.8	84.1	82.2	83.3	85.3

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	55.7	40.4	40.8	108	1,124	387	9.82	73.3	230	375
Short-term investments			21.9	0	105	99.7	93.2	104	119	124
Receivables	495	504	507	434	242	302	297	272	260	230
Other current assets	13.8	37.2	17.2	11.8	61.8	18.9	13.3	12.3	5.09	8.88
Total current assets	587	627	660	732	1,549	841	428	483	640	764
Property, plant and equipment	103	124	90.4	72.7	76.2	70.2	73.3	75.6	39.2	39.2
Lease right-of-use assets			0	56.4	44.9	51.3	55.8	61.7	34.1	31.1
Goodwill	3,845	4,284	4,061	1,480	1,478	1,505	1,532	1,384	1,243	1,261
Intangible assets	669	640	313	28.6	26.6	21.6	18.5	21.2	11.6	16.9
Long-term investments			69.7	0
Other non-current assets	56.5	91.9	81.2	48.6	107	131	123	82.2	76.6	58.2
Total assets	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153	2,247
Accounts payable	28.5	34.6	31.1	35.4	59.8	36.6	31.9	34.6	46.4	37.2
Short-term debt	20	1.4	0.25			2.49	14.9	14.9	20.5	26.8
Total current liabilities	449	531	503	542	444	427	427	389	434	459
Long-term debt	1,679						632	618	597	571
Lease liabilities			0	44.6	41	41.4	44.2	47.2	31.9	25.7
Other non-current liabilities	45.2	57.9	31.8	22.8	45.3	42.3	39.4	30.6	32.9	30.3
Total liabilities	2,579	2,801	2,850	2,647	2,600	1,826	1,456	1,371	1,388	1,381
Total debt	1,699	1,846	1,970	1,700	1,700	990	637	622	611	600
Paid-in capital	974	1,017	993	988	1,029	1,050	984	1,000	1,014	948
Retained earnings	1,786	2,048	2,094	510	-286	-155	-89.1	-149	-249	-83.2
Other comprehensive income			0	0.08	3.53	1.32	-3.74	-2.21	-1.07	0.61
Shareholders' equity	2,761	3,066	3,088	1,499	747	896	892	849	765	866
Minority interests				0	0.23	0.21	0
Total equity	2,761	3,066	3,088	1,499	748	897	892	849	765	866
Total liabilities and equity	5,339	5,867	5,937	4,146	3,348	2,723	2,348	2,220	2,153	2,247
Shares outstanding	93.7	93.7	87.8	84.2	85.6	86.4	82.9	84	85.9	83

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	325	320	269	-1,498	-796	131	66.3	-60.4	-99.1	165
Depreciation and amortization	89.3	78.9	24.4	25.9	28.4	32.1	35.6	36.2	32.2	21.8
Stock-based compensation	34	28.8	36.6	33.4	39	19	16.1	12.3	11.9	18
Deferred income tax	18.1	-61.2	-35.9	-55.7	36.3	-31.2	-22.8	3.24	-2.13	52.2
Change in receivables	-34	10.8	-35.3	6.51	37.9	-72.7	-5.54	26.3	10.3	30.6
Change in payables	11.6	34.9	-3.04	46.2	47.9	21.3	0.42	-11.9	51.1	28.3
Cash from operations	444	511	314	358	205	76.7	167	137	207	271
Acquisitions	-762	-531	-65.4	47	-2.23	-29.9	-28.2	-6.67	-8.17	-23.2
Purchases of investments	-61	-27.7	-15.9	-35.1	-61.8	-15.1	-17.3	-31.9	-64.5	-29.9
Sales and maturities of investments	41.3	25.4	13.7	51.1	33.4	16.5	16.9	22.9	52.5
Cash from investing	-821	-577	-143	102	816	-53.1	-57	-48.2	-35.4	-18.3
Debt issued		0	500	500	0	0	650	0	0
Debt repaid					0	-760	-1,047	0	0
Stock issued	22	23.3	16.3	11.3	7.01	6.85	5.4	4.91	3.64	3.18
Share buybacks	-61.8	-70.2	-302	-145	-8.49	-4.72	-88.5	-0.92	-1.7	-86.7
Cash from financing	382	89.7	-171	-393	-4.16	-760	-488	-25.7	-14.5	-107
Net change in cash	4.13	24.5	0.33	67.1	1,016	-736	-378	63.4	157	145
Interest paid	60.5	73.8	82.5	95.4	110	86.5	116	42.3	40	34.4
Income taxes paid	176	75.4	185	86.3	-27.8	54.7	26.9	30.8	4.67	1.72

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $26.31 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Operating margin	11.0%	Operating income / revenue.
EBITDA margin	12.2%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	11.6%	Pre-tax income / revenue.
Net margin	9.0%	Net income / revenue.
Operating cash flow margin	12.7%	Cash from operations / revenue.
Effective tax rate	22.7%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	19.8%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	8.2%	Net income / average total assets.
Return on invested capital (ROIC)	14.2%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	0.9%	Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue	1.2%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-4.9%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-1.0%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	2.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income CAGR, 3y	6.5%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	16.3%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA CAGR, 3y	3.5%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	12.8%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income CAGR, 3y	35.6%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 3y	34.9%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y	31.2%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	17.5%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	5.8%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	13.2%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-1.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	3.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	4.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-1.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-7.7%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	2.3%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.5%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.4%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.32x	Current assets / current liabilities.
Quick ratio	1.26x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.81x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.66x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	27.4%	Total debt / total assets.
Liabilities / assets	58.6%	Total liabilities / total assets.
Net debt	$180.0M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	0.75x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	6.31x	Operating income / interest expense.
Working capital	$158.6M	Current assets - current liabilities.
Goodwill and intangibles / assets	60.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$401.8M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.92x	Revenue / average total assets.
Fixed asset turnover	50.4x	Revenue / average property, plant and equipment.
Receivables turnover	8.57x	Revenue / average receivables.
Days sales outstanding	43 days	365 x average receivables / revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	$2.15	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$23.96	Revenue / diluted weighted shares.
Operating cash flow per share	$3.03	Cash from operations / diluted weighted shares.
Book value per share	$10.85	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$4.95	Tangible book value / shares outstanding.
Cash per share	$4.98	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$2.14B	Share price x shares outstanding.
Enterprise value	$2.32B	Market cap + total debt - cash - short-term investments.
P/E	12.2x	Market cap / net income. Only when net income is positive.
P/S	1.10x	Market cap / revenue.
P/B	2.43x	Market cap / shareholders' equity. Only when equity is positive.
P/OCF	8.66x	Market cap / cash from operations, when positive.
EV/Sales	1.19x	Enterprise value / revenue.
EV/EBIT	10.8x	Enterprise value / operating income, when both are positive.
EV/EBITDA	9.72x	Enterprise value / EBITDA, when both are positive.
Earnings yield	8.2%	Net income / market cap (the inverse of P/E).
Shareholder yield	7.0%	(Dividends paid + share buybacks) / market cap.
PEG	0.35x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was Pediatrix Medical Group, Inc.'s revenue in fiscal 2025?

Pediatrix Medical Group, Inc. reported revenue of $1.91B for fiscal 2025, 4.9% lower than the year before.

Was Pediatrix Medical Group, Inc. profitable in fiscal 2025?

Yes. Net income was $165.4M, a net margin of 8.6%.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Pediatrix Medical Group, Inc.